Hypothalamic expression of PD-L1: does it mediate hypothalamitis?
作者信息
Iervasi Erika, Strangio Antonella, Saverino Daniele
机构信息
Department of Experimental Medicine, University of Genova, Via De Toni, 14, 16132, Genova, Italy.
IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy.
出版信息
Cell Mol Immunol. 2019 Jun;16(6):625-626. doi: 10.1038/s41423-019-0232-2. Epub 2019 Apr 12.
Abstract
摘要
相似文献
1
Hypothalamic expression of PD-L1: does it mediate hypothalamitis?
Cell Mol Immunol. 2019 Jun;16(6):625-626. doi: 10.1038/s41423-019-0232-2. Epub 2019 Apr 12.
2
New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
3
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.
4
[Strategies around PD-L1 testing in France].
Ann Pathol. 2017 Feb;37(1):3-4. doi: 10.1016/j.annpat.2016.11.003. Epub 2017 Jan 17.
5
The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Oral Oncol. 2019 Mar;90:67-73. doi: 10.1016/j.oraloncology.2019.01.018. Epub 2019 Feb 5.
6
Atypical autoimmune adverse effects with checkpoint blockade therapies.
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.
7
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
Clin Lung Cancer. 2019 Jul;20(4):e489-e491. doi: 10.1016/j.cllc.2019.04.007. Epub 2019 Apr 19.
8
Role of immune-checkpoint inhibitors in lung cancer.
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075.
9
Pembrolizumab as second-line treatment for urothelial cancer.
Lancet Oncol. 2017 Apr;18(4):e197. doi: 10.1016/S1470-2045(17)30156-0. Epub 2017 Feb 24.
10
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
J Cell Physiol. 2019 Feb;234(2):1313-1325. doi: 10.1002/jcp.27172. Epub 2018 Sep 7.
引用本文的文献
1
Primary autoimmune hypothalamitis: management strategies and long-term outcomes in a tertiary care setting with a focused review of literature.
Endocrine. 2025 May 21. doi: 10.1007/s12020-025-04267-y.
2
Immunotherapy-Related Hypophysitis: A Narrative Review.
Cancers (Basel). 2025 Jan 27;17(3):436. doi: 10.3390/cancers17030436.
3
Circulating anti-hypothalamus antibodies in celiac patients: tissue transglutaminase friend or foe?
Immunol Res. 2023 Dec;71(6):839-848. doi: 10.1007/s12026-023-09394-0. Epub 2023 May 23.
4
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.
Cancers (Basel). 2023 Mar 28;15(7):2016. doi: 10.3390/cancers15072016.
5
Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.
Front Endocrinol (Lausanne). 2022 Mar 21;13:840971. doi: 10.3389/fendo.2022.840971. eCollection 2022.
6
Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?
Front Oncol. 2022 Mar 3;12:798517. doi: 10.3389/fonc.2022.798517. eCollection 2022.
7
Anti-hypothalamus autoantibodies in anorexia nervosa: a possible new mechanism in neuro-physiological derangement?
Eat Weight Disord. 2022 Oct;27(7):2481-2496. doi: 10.1007/s40519-022-01388-5. Epub 2022 Mar 16.
8
Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle.
Cancers (Basel). 2022 Feb 18;14(4):1057. doi: 10.3390/cancers14041057.
9
Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies.
Cancers (Basel). 2021 Aug 11;13(16):4036. doi: 10.3390/cancers13164036.
本文引用的文献
1
Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment.
Eur J Cancer. 2018 Nov;104:247-249. doi: 10.1016/j.ejca.2018.09.016. Epub 2018 Oct 28.
2
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12.
3
Management of toxicities of immune checkpoint inhibitors.
Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6.
4
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Sci Transl Med. 2014 Apr 2;6(230):230ra45. doi: 10.1126/scitranslmed.3008002.
Zotero 插件